Congress Park Capital LLC Sells 875 Shares of Zoetis Inc. (NYSE:ZTS)

Congress Park Capital LLC cut its stake in Zoetis Inc. (NYSE:ZTS) by 8.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,215 shares of the company’s stock after selling 875 shares during the period. Congress Park Capital LLC’s holdings in Zoetis were worth $1,559,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Operose Advisors LLC acquired a new stake in shares of Zoetis during the 3rd quarter worth approximately $58,000. Mutual Advisors LLC grew its holdings in Zoetis by 4.0% during the third quarter. Mutual Advisors LLC now owns 3,195 shares of the company’s stock valued at $556,000 after purchasing an additional 122 shares during the period. Mather Group LLC. boosted its holdings in shares of Zoetis by 2.0% in the third quarter. Mather Group LLC. now owns 3,638 shares of the company’s stock valued at $633,000 after buying an additional 73 shares during the period. Vinva Investment Management Ltd boosted its holdings in shares of Zoetis by 14.4% in the third quarter. Vinva Investment Management Ltd now owns 13,365 shares of the company’s stock valued at $2,326,000 after buying an additional 1,687 shares during the period. Finally, Treasurer of the State of North Carolina boosted its holdings in shares of Zoetis by 0.4% in the third quarter. Treasurer of the State of North Carolina now owns 215,435 shares of the company’s stock valued at $37,481,000 after buying an additional 808 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.5 %

ZTS traded down $0.92 during mid-day trading on Friday, reaching $175.54. 979,057 shares of the stock were exchanged, compared to its average volume of 2,944,148. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The stock has a market capitalization of $80.10 billion, a PE ratio of 33.81, a price-to-earnings-growth ratio of 2.65 and a beta of 0.88. The company has a 50 day moving average price of $167.68 and a two-hundred day moving average price of $178.94. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.31 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 33.33%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. Stifel Nicolaus dropped their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. Barclays dropped their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. The Goldman Sachs Group dropped their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, HSBC decreased their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $211.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.